However, our meta-analysis indicated that enteral lactoferrin supplementation did not reduce the incidence of sepsis, NEC stage II or III, all-cause mortality, sepsis-related mortality, and other adverse outcomes, which were inconsistent with previous meta-analyses. The gene discussed is LTF; the disease is necrotizing enterocolitis.